Revenue
2023
2024
2025
Tonix Pharmaceuticals Holding Corp. (TNXP)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.1M | $10.1M | $7.8M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $44.5M | $40.0M | $86.7M | $81.9M | $68.8M | $36.2M | $18.2M | $17.6M | $13.3M | $28.5M | $35.5M | $18.6M | $4.7M | $2.6M | $1.2M | $584,298 | — | — |
| Operating expenses | — | — | — | — | — | — | — | — | — | — | $48.2M | $27.7M | $10.9M | $6.7M | $3.4M | $1.9M | — | — |
| Operating income | −$125.7M | −$136.7M | −$118.4M | −$112.1M | −$92.3M | −$50.5M | −$28.8M | −$26.3M | −$21.3M | −$39.0M | −$48.2M | −$27.7M | −$10.9M | −$6.7M | −$3.4M | −$1.9M | — | — |
| EBITDAderived | −$123.8M | −$133.3M | −$114.1M | −$110.8M | −$92.3M | −$50.5M | −$28.8M | −$26.3M | −$21.2M | −$38.8M | −$48.0M | −$27.6M | −$10.9M | — | — | — | — | — |
| Net income | −$124.0M | −$130.0M | −$116.7M | −$110.2M | −$92.3M | −$50.5M | −$28.6M | −$26.1M | −$21.1M | −$38.8M | −$48.1M | −$27.6M | −$10.9M | −$9.4M | −$3.5M | −$2.0M | −$221,000 | −$202,000 |
| Basic EPSper diluted share | -$14.57 | -$176.60 | -$14,720.25 | -$20.01 | -$8.10 | -$0.55 | -$19.33 | -$259.85 | -$31.69 | -$15.41 | -$28.62 | -$2.77 | -$3.37 | -$5.58 | -$3.24 | -$0.18 | — | — |
| Diluted EPSper diluted share | -$14.57 | -$176.60 | -$14,720.25 | -$20.01 | -$8.10 | -$0.55 | -$19.33 | -$259.85 | -$31.69 | -$15.41 | -$28.62 | -$2.77 | -$3.37 | -$5.58 | -$3.24 | -$0.18 | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026Form 4 | Taylor Carolyn E.Director | BuyCommon Stock, $0.001 par value | 1.4K | $10.55 | $14.9K | 1.8K |
| Jun 9, 2026Form 4 | LEDERMAN SETHChief Executive Officer | BuyCommon Stock, $0.001 par value | 5.0K | $11.79 | $58.9K | 9.0K |
| Jun 8, 2026Form 4 | Stillwell Richard NewcombDirector | BuyCommon Stock, $0.001 par value | 5.0K | $11.65 | $58.3K | 5.0K |
| Mar 31, 2026Form 4 | LEDERMAN SETHChief Executive Officer | BuyCommon Stock, $0.001 par value · indirect | 5.0K | $12.62 | $63.1K | 20.0K |
| Mar 18, 2026Form 4 | LEDERMAN SETHChief Executive Officer | BuyCommon Stock, $0.001 par value · indirect | 15.0K | $14.89 | $223.3K | 15.0K |